Summit Therapeutics Inc.

Pharmaceutical Preparations

SMMTStrained3 of 8 basics passed

$17.55

+2.21%

Market cap $14.0B

$17.55

+2.21%

Market cap $14.0B

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic.

It is a $14.0B healthcare company. It holds more cash than debt.

Website: smmttx.com
Location: Miami, FL
Employees: 265
Sector: Healthcare

Share price · 3 years

$1.78 → $17.55+886.0%

price only — dividends excluded

Key facts · TTM

Loss: spends more than it earns; -$2.53B
Free cash flow: cash left after running the business; -$932M
Net cash: more cash than debt; $670M
Shares: up 86% since 2020 — dilution; 776.8M

Revenue, last 5 years

52-week range

Low $12.43$17.55High $26.38

Today's price is 37% of the way from the year's low to its high.

Valuation vs own history

P/S

4579.9×

P/B

22.3×

44%

Share of the last ~5 years that was pricier than today (pricier than usual). Based on the daily valuation record.

Standing in Healthcare

Size$14.0Btop 67%
Net margin-9027%top 100%
Return on equity-169%top 96%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation20

P/E vs own historyn/a · 10/25
FCF yield-6.7% · 0/25
P/S14653.3x · 0/25
EV/EBITDAn/a · 10/25

Growth0

Revenue CAGRn/a · 0/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROICn/a · 0/25
ROE-168.9% · 0/25
Net margin-9027.1% · 0/25
Operating margin-8108.3% · 0/25

Health50

Altman Zn/a · 0/25
Current ratio6.96 · 25/25
Interest coverage-121.3x · 0/25
Net cash / debtNet cash · 25/25

Quality0

Piotroski F1/9 · 0/25
Beneish Mn/a · 0/25
FCF conversionn/a · 0/25
Margin stabilityσ 3736.6% · 0/25

Moat0

ROIC >12% years0/3 yrs · 0/25
Median gross marginn/a · 0/25
FCF-positive years0/7 yrs · 0/25
Worst-year net marginworst -9226.1% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

Q2 2026Insiders
6 open-market insider purchases
~7.9M shares bought by insiders
FY2023Financial
Became debt-free
cash now exceeds total debt

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$33 685 today — price return only

265 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

Net cash position after subtracting debt from cash

Watch-outs

Not profitable — 9027.1% net margin
Negative free cash flow (-$932.2M)
Thin interest coverage (-121.3×)
Loss-making in 6 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

3 of 8 checks passed

Revenue growing — the company sells more than a year agono data
Profitable — makes more than it spends-$2.53B TTM
Profit growing — earnings are higher than last year+77.4% YoY
Generates cash — cash left after running and investing-$932M TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$14.0B market cap
Not printing shares — share count not ballooning — you keep your slice+40.4% shares over ~5y
Proven track record — years of profitability behind it0/7 profitable years
Financially stable — balance sheet not near distresshealth score 25/100
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonSummit Therapeutics Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
SMMT this company	$14.0B	—	—	—	Strained
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: SMMT vs LLY · SMMT vs JNJ · SMMT vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 5Buy 11Hold 8

Appendix · Financial records

The full statements behind this CV, FY2020–FY2026. For readers who want to check the numbers.

Profit & lossRevenue — · net income -$2.53B (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

RevenueNet income

Revenue (TTM)

—

Net income (TTM)

-$2.53B

Operating margin

-8108.3%

Income statement — full detail

Figures in USD billions · EPS in USD

	2021	2022	2023	2024	2025	2026
Revenue	0.0	0.0	0.0	0.0	—	—
Gross profit	0.0	0.0	—	—	—	—
Operating income (EBIT)	-0.2	-0.2	-0.2	-0.5	-2.7	-0.6
Net income	-0.2	-0.2	-2.3	-0.5	-2.6	-0.6
EPS (diluted)	-0.38	-0.34	-3.70	-0.74	-3.52	-0.77

Cash flowFree cash flow -$932M · operating cash flow -$930M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$932M

Operating cash flow (TTM)

-$930M

Cash flow statement — full detail

Figures in USD billions

	2021	2022	2023	2024	2025	2026
Operating cash flow	-0.2	-0.1	-0.2	-0.3	-0.7	-0.4
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	-0.2	-0.1	-0.2	-0.3	-0.7	-0.4
FCF margin	-5178.8%	-6892.6%	—	—	—	—

Balance sheetAssets $752M · net cash $670M (FY2026)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $752M of assets is financed

16%

84%

Liabilities $122M — borrowed moneyEquity $630M — owners' stake

Cash vs debt

Total debt $20.4M − cash $691M = net cash $670M

Cash on hand covers all debt.

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

-121.3x

EBIT ÷ interest expense

ROE

-168.9%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2021	2022	2023	2024	2025	2026
Cash & equivalents	0.1	0.3	0.2	0.4	0.7	0.7
Total assets	0.1	0.7	0.2	0.4	0.8	0.8
Total liabilities	0.0	0.5	0.1	0.0	0.1	0.1
Total debt	0.0	0.5	0.1	0.0	0.0	0.0
Equity	0.1	0.1	0.1	0.4	0.7	0.6
Net debt	-0.1	0.2	-0.1	-0.4	-0.7	-0.7

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of SMMT on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $17.55 · market cap $14.0B.